Current Report Filing (8-k)
November 09 2017 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported):
November 9, 2017
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
001-37761
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act
☐
Item 2.02
Results of Operations and
Financial Condition.
See
Item 8.01.
Item 8.01
Other
Events.
Today, VistaGen Therapeutics Inc. (the
“
Company
”) announced its financial results for the
three- and six-month period ended September 30, 2017, and provided
investors with a corporate update. A copy of the press release is
attached hereto as Exhibit 99.1.
The information furnished herein and therein shall
not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“
Exchange
Act
”), or otherwise
subject to the liabilities of that Section, or incorporated by
reference in any filing under the Exchange Act or the Securities
Act of 1933, as amended, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen Therapeutics, Inc.
|
|
|
|
Date:
November 9, 2017
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press
release issued by VistaGen Therapeutics Inc., dated November 9,
2017.
|
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024